Evidence map›Paper›PMID 40465145›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2025

Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.

J Bradley Layton, Ryan Ziemiecki, Catherine B Johannes, Manel Pladevall-Vila, Anam M Khan, Natalie Ebert, Csaba P Kovesdy, Christian Fynbo Christiansen, Aníbal García-Sempere, Hiroshi Kanegae and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

J Bradley LaytonRTI Health Solutions, Research Triangle Park, NC, USA.
Ryan ZiemieckiRTI Health Solutions, Research Triangle Park, NC, USA.
Catherine B JohannesRTI Health Solutions, Waltham, MA, USA.
Manel Pladevall-Vila *RTI Health Solutions, Barcelona, Spain.
Anam M KhanRTI Health Solutions, Waltham, MA, USA.
Natalie EbertInstitute of Public Health, Charité-Universitätsmedizin, Berlin, Germany.
Csaba P KovesdyDivision of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Christian Fynbo ChristiansenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Aníbal García-SempereHealth Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.
Hiroshi KanegaeGenki Plaza Medical Centre for Health Care, Tokyo, Japan.
Craig I ColemanUniversity of Connecticut School of Pharmacy, Storrs, CT, USA.
Michael WalshDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Ina Trolle AndersenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Clara Rodríguez-BernalHealth Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.
Celia Robles CabaniñasHealth Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.
Reimar W ThomsenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Alfredo E FarjatBayer AG, Müllerstrasse 178, 13353, Berlin, Germany.
Alain Gay *Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany.
Patrick GeeNational Kidney Foundation Advocacy, Richmond, VA, USA.
Isabel HurtadoHealth Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.
Naoki KashiharaKawasaki Geriatric Medical Center, Okayama, Japan.
Philip Vestergaard MunchDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Fangfang LiuBayer AG, Müllerstrasse 178, 13353, Berlin, Germany.
Suguru OkamiBayer AG, Müllerstrasse 178, 13353, Berlin, Germany.
Satoshi YamashitaBayer AG, Müllerstrasse 178, 13353, Berlin, Germany.
Yuichiro YanoDepartment of General Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan.
David Vizcaya *Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany.
Nikolaus G OberprielerBayer AG, Müllerstrasse 178, 13353, Berlin, Germany. niki.oberprieler@bayer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPeople with chronic kidney disease (CKD) and type 2 diabetes (T2D) have an increased risk of kidney failure and cardiovascular disease. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have shown cardiorenal protective effects. The objective of this multinational, multidatabase study was to describe the incidence of kidney and cardiovascular outcomes in separate, non-mutually exclusive cohorts of patients with CKD and T2D who initiated either an SGLT2i or a GLP-1 RA.

methodsData describing adults (≥ 18 years) with T2D and CKD who were new users of either SGLT2i or GLP-1 RA from 2012 to 2019 were assessed from population-based Danish National Health Registers (DNHR) and Valencia Health System Integrated Database (VID), hospital-based Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex), and US Optum

resultsSGLT2i cohorts comprised 12,501 patients in DNHR, 22,404 in VID, 811 in J-CKD-DB-Ex, and 54,308 in Optum

conclusionUnderstanding the incidence of kidney failure and cardiovascular outcomes in people receiving antidiabetic medications with cardiorenal protective effects is important for future studies aiming to compare the incidence of kidney and cardiovascular outcomes related to new and existing CKD treatments.

Indexed as

Chronic kidney diseaseDiabetes mellitus, Type 2Drug utilizationFOUNTAINGlucagon-like peptide-1 receptor agonistsRenal insufficiency, chronicSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID40465145
PMCPMC12317948

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.